Clinical trials: Patients With Major Depressive Disorder
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE…
- Trial name
- OPAL (NCT00326144)
- Testing
- Quetiapine fumarate
- Where
- 34 sites in United States
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Badalona Major Depressive Disorder Database Study
A retrospective study using a data base of anonymized medical records. The purpose of the study is to examine the different therapeutic strategies for the management of patients with major depressive disorder (MDD) and suboptimal…
- Trial name
- NCT01446692
- Where
- Spain
- Volunteers
- 2,260 people
- Sponsor
- AstraZeneca
Vitamin b6 Level & Depression
Assesment of Vitamin B6 Level in Patients With Major Depressive Disorder
Estimation of vitamin B 6 levels in diagnosed major depressive disorder patients and their relation to the severity of the disease
- Trial name
- NCT05649293
- Testing
- measure vitamin b6 in serum
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Assiut University
Major Depressive Disorder
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD.
- Trial name
- NCT00644358
- Testing
- vilazodone
- Where
- 38 sites in United States
- Volunteers
- 616 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis
This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major…
- Trial name
- PGX-AMG (NCT02443584)
- Testing
- pharmacogenetic testing
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Major Depressive Disorder
The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder
Objective There is growing evidence showing a relation between depression, metabolic syndrome, diabetes, cardiovascular disease (1), serum lipid profile (2,3) and body weight (4), as well as the effects of some of the…
- Trial name
- NCT01418638
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Ziv Hospital
Treatment Resistant Depression
Deep Brain Stimulation in Treatment Resistant Depression
Recurrent major depressive disorder affects about 3-5% of the population. It is anticipated that by 2020, depression will be the most common cause of disability worldwide in the 18-55 age group.
- Trial name
- NCT01435148
- Testing
- Deep Brain Stimulation, implanted
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- North Bristol NHS Trust
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
- Trial name
- NCT00034944
- Testing
- MK0869, aprepitant
- Volunteers
- 495 people
- Sponsor
- Merck Sharp & Dohme LLC
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Depression
The Impact of Psychological Interventions on Psychometric and Immunological Measures in Patients With Major Depression
The objective of this study is to compare the impact of i) Cognitive Behavioral Therapy (CBT) combined with exercise, ii)CBT combined with euthymic therapy, and iii) 'Cognitive Behavioral Analysis System of Psychotherapy' (CBASP)…
- Trial name
- NCT01464463
- Testing
- CBT - active, CBT - euthymic, CBASP
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Philipps University Marburg
Major Depressive Disorder
Transcranial Alternating Current Stimulation (tACS) on Serotonin-1A Receptor in Depression
This study will apply a comprehensive tools that integrates neuroimaging, psychological evaluation, and sleep monitoring through 18F-MPPF PET/MR, neuropsychological tests, and polysomnography (PSG) to explore the neurobiological…
- Trial name
- NCT06211140
- Testing
- tACS, Control
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Major Depressive Disorder, Cancer
Vortioxetine for Cancer Patients With Depression: An Observational Study
The purpose of this observational antidepressant study is to determine the efficacy of vortioxetine on depression and cognitive function, and elucidate its potential effects on quality of life in patients with cancer (of any…
- Trial name
- NCT04253678
- Testing
- Vortioxetine
- Where
- 8 sites in Malaysia
- Volunteers
- 140 people
- Sponsor
- University of Malaya
Major Depressive Disorder (MDD)
Evaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode
The aim of this clinical investigation is to find out whether the EMOCARE emotional monitoring software provides consistent results compared with the tools available for assessing the emotional state of patients suffering from…
- Trial name
- EMC1 (NCT06601140)
- Testing
- EMOCARE software
- Where
- 11 sites in France
- Volunteers
- 104 people
- Sponsor
- Emobot
Major Depression
Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression
The investigators will investigate in a sham controlled staggered onset design antidepressant effects and safety of deep brain stimulation (DBS) to the superolateral branch of the main medial forebrain bundle (slMFB).
- Trial name
- FORESEEII (NCT01778790)
- Testing
- Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- University Hospital, Bonn
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Sleep Disturbances
Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder
To assess effects of brexpiprazole on sleep patterns of depressed patients with sleep disturbances.
- Trial name
- NCT01942733
- Testing
- Brexpiprazole
- Volunteers
- 44 people
- Sponsor
- H. Lundbeck A/S
Randomized Controlled Trial
Cost-utility and Physiological Effects of ACT and BATD in Patients With Chronic Pain and Depression
Objectives: (1) To analyze the effectiveness of adding a group-based form of Acceptance and Commitment Therapy (ACT) or a behavioural activation program for depression (TACD) to the treatment as usual (TAU) for patients diagnosed…
- Trial name
- IMPACT (NCT04140838)
- Testing
- Acceptance and Commitment Therapy (ACT), Behavioral Activation Therapy for Depression (BATD), Treatment as Usual (TAU)
- Where
- 2 sites in Spain
- Volunteers
- 234 people
- Sponsor
- Fundació Sant Joan de Déu
Bipolar Depression
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as…
- Trial name
- NCT06372964
- Testing
- Lumateperone
- Where
- 68 sites in United States, Colombia and 2 more
- Volunteers
- 384 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder
Antidepressant Adherence Via AD_IVR
Antidepressants are the most frequently prescribed class of psycho¬tropic medications and the most common treatment for depression and anxiety disorders-yet patient adherence is poor and is widely viewed as contributing to…
- Trial name
- AD_IVR (NCT01188135)
- Testing
- Interactive voice messaging or Interactive voice messaging + psycho ed materials
- Where
- United States
- Volunteers
- 6,058 people
- Sponsor
- Kaiser Permanente